Screener
ClearPoint Neuro CLPT Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by ClearPoint Neuro in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: ClearPoint Neuro’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221890
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Payment of At-The-Market offering costs | — | (78) |
| Proceeds from stock option exercises | 148 | 21 |
| Payments for taxes related to net share settlement of equity awards | (1,993) | (1,305) |
| Net cash flows from financing activities | (1,845) | (1,362) |
| Net change in cash, cash equivalents and restricted cash | (10,457) | (7,717) |
| Cash, cash equivalents and restricted cash, beginning of period | 46,973 | 20,104 |
| Cash, cash equivalents and restricted cash, end of period | $36,516 | $12,387 |
| Cash and cash equivalents | 35,593 | 12,387 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is ClearPoint Neuro's financing cash flow?
- ClearPoint Neuro (CLPT) reported financing cash flow of -$1.85M in Q1 2026.
- How has ClearPoint Neuro's financing cash flow changed year-over-year?
- ClearPoint Neuro's financing cash flow decreased by 35.5% year-over-year, from -$1.36M to -$1.85M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about ClearPoint Neuro's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude